We are live on ! Find out more
TGI

TRV GP III Portfolio holdings

AUM $6.14M
1-Year Est. Return 45.44%
This Fund
S&P 500
This Quarter Est. Return
+47.14%
1 Year Est. Return
+45.44%
3 Year Est. Return
+169.98%
5 Year Est. Return
+802.39%
10 Year Est. Return
–
AUM
$685M
AUM Growth
+$318M
Cap. Flow
+$129M
Cap. Flow %
18.86%
Top 10 Hldgs %
100%
Holding
6
New
1
Increased
–
Reduced
–
Closed
1

Top Buys

Rank Stock Value
1
PLRX icon
Pliant Therapeutics
PLRX
+$155M

Top Sells

Rank Stock Value
1
NTGN
Neon Therapeutics, Inc. Common Stock
NTGN
+$25.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RVMD icon
1
Revolution Medicines
RVMD
$42.1B
$285M 41.58%
9,024,031
– –
PLRX icon
2
Pliant Therapeutics
PLRX
$65M
$190M 27.66%
+5,839,160
New +$155M
FULC icon
3
Fulcrum Therapeutics
FULC
$288M
$109M 15.92%
5,962,202
– –
VYGR icon
4
Voyager Therapeutics
VYGR
$189M
$80.7M 11.77%
6,391,176
– –
JNCE
5
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$21M 3.07%
3,048,780
– –
NTGN
6
DELISTED
Neon Therapeutics, Inc. Common Stock
NTGN
– –
-9,741,636
Closed -$25.7M

Similar funds

TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
GIP
General Industrial Partners London, United Kingdom $2.57M AUM
LCMP
Linse Capital Management PR San Juan, Puerto Rico $2.31M AUM
SCM
SevenOneSeven Capital Management Lancaster, Pennsylvania $2.17M AUM 8.67% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

TRV GP III's Q2 2020 Portfolio in Review

As of Q2 2020, TRV GP III held 6 positions worth $685M, up 86% from $368M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

TRV GP III deployed $129M of net new capital in Q2 2020, opening 1 new position. Its largest new stake was Pliant Therapeutics: 5,839,160 shares worth $190M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the most notable exit was Neon Therapeutics, Inc. Common Stock, an estimated $25.7M sold.

  • TRV GP III's largest Q2 2020 buy was Pliant Therapeutics: 5,839,160 shares worth $190M.
  • TRV GP III fully exited Neon Therapeutics, Inc. Common Stock in Q2 2020, selling an estimated $25.7M.
  • TRV GP III's ten largest holdings make up 100% of its $685M portfolio in Q2 2020.
  • TRV GP III opened 1 new position and closed 1 in Q2 2020.
  • TRV GP III's portfolio value rose 86% quarter-over-quarter to $685M.

Based on TRV GP III's 13F filing for Q2 2020, filed 7 Aug 2020.